---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-008195"
form_type: "8-K"
ticker: "BLGO"
cik: "0000880242"
company_name: "BIOLARGO, INC."
filed_at: "2022-04-04T23:59:59+00:00"
generated_at: "2026-06-26T10:02:17.509469+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioLargo 2021 revenue $2.53M (+4%), net loss down 29% to $6.9M, debt cut to $0.68M

## Summary
- Revenue of $2,531,000 for FY2021, a 4% increase from 2020; Q4 revenue $784,000 (+10% QoQ).
- Net loss reduced 29% to $6.9M, including $1.9M non-cash option expense and $342K impairment.
- Total debt slashed from $2.9M to $681K; total liabilities down from $5.2M to $2.1M.
- AEC PFAS treatment passed tests with municipality and federal agency; Garratt-Callahan MLD prototype completed.
- Ikigai partnership for pet odor product exceeds initial projections; Clyra's Bioclynse secures two hospital customers.

## SEC filing metadata
- accession: 0001437749-22-008195
- form_type: 8-K
- ticker: BLGO
- cik: 0000880242
- company_name: BIOLARGO, INC.
- filed_at: 2022-04-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/880242/000143774922008195/0001437749-22-008195-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/880242/000143774922008195/blgo20220404_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-008195
- JSON: https://secwatch.observer/filing/0001437749-22-008195.json
- Plain text: https://secwatch.observer/filing/0001437749-22-008195.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.